Research - Houston, Texas, United States
BrYet is a privately-owned biotech company with operations focused on the discovery and development of physics-based transtherapeutics for the treatment of metastatic liver and lung cancers. BrYet's discovery program of injectable nanoparticle generators has yielded a lead drug candidate, ML-016, which will be studied in humans in a Phase I clinical trial and has the potential to treat a broad range of patients with hard to treat cancers.
Outlook
GoDaddy Hosting
Mobile Friendly